

RECEIVED
CENTRAL FAX CENTER

Application No. 09/724,575
Supplemental Amendment dated January 31, 2005

JAN 31 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-10. (Canceled)

11. (Previously Presented) A method of therapeutically treating a patient suffering from Alzheimer's disease, comprising administering to the patient a dosage of an antibody or antibody fragment thereof that specifically binds synuclein-NAC and a dosage of an antibody or antibody fragment thereof that specifically binds to A β , therapeutically treat the disease.

12-57. (Canceled)

58. (Currently Amended) A method of prophylactically treating a patient susceptible to Alzheimer's disease, comprising administering to the patient a dosage of an antibody or antibody fragment thereof that specifically binds synuclein-NAC and a dosage of an antibody or antibody fragment thereof that specifically binds to A β , and thereby effecting prophylaxis of the disorder disease.

59-73. (Canceled)

74. (Previously Presented) The method of claim 11, wherein the antibodies or antibody fragments are administered with a carrier.

75. (Previously Presented) The method of claim 11, wherein the antibodies or antibody fragments are administered intraperitoneally, orally, subcutaneously, intramuscularly, intranasally, topically, or intravenously.

76. (Previously Presented) The method of claim 11, wherein the antibodies or antibody fragments are administered in multiple dosages over a period of at least six months.

Application No. 09/724,575
Supplemental Amendment dated January 31, 2005

77. (Previously Presented) The method of claim 11, wherein the antibodies or antibody fragments are administered as a sustained release composition.

78. (Previously Presented) The method of claim 58, wherein the antibodies or antibody fragments are administered with a carrier.

79. (Previously Presented) The method of claim 58, wherein the antibodies or antibody fragments are administered intraperitoneally, orally, subcutaneously, intramuscularly, intranasally, topically, or intravenously.

80. (Previously Presented) The method of claim 58, wherein the antibodies or antibody fragments are administered in multiple dosages over a period of at least six months.

81. (Previously Presented) The method of claim 58, wherein the antibodies or antibody fragments are administered as a sustained release composition.